Home page Home page
AstraZeneca

Versican Plus DHPPi
canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus


PACKAGE LEAFLET:

Ve rsican Plus DHPPi lyophilisate and solve nt for suspe nsion for inje ction for dogs


  1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT


    Marketing authorisation holde r:


    Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM


    Manufacturer responsible for batch release:


    Bioveta, a.s., Komenského 212,

    683 23 Ivanovice na Hané, CZECH REPUBLIC


  2. NAME OF THE VETERINARY MEDICINAL PRODUCT


    Versican Plus DHPPi lyophilisate and solvent for suspension for injection for dogs


  3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)


    Each dose of 1 ml contains:


    Active substance s:


    Lyophilis ate (live atte nuate d):


    Minimum Maximum

    Canine distemper virus, strain CDV Bio 11/A 103.1 TCID50* 105.1 TCID50 Canine adenovirus Type 2, strain CAV-2 Bio 13 103.6 TCID50* 105.3 TCID50 Canine parvovirus Type 2b, strain CPV-2b Bio 12/B 104.3 TCID50* 106.6 TCID50 Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15 103.1 TCID50* 105.1 TCID50


    So lve nt:

    Water for injections (Aqua ad iniectabilia) 1 ml

    * Tissue culture infectious dose 50%. Lyophilisate: spongy matter of white colour.

    Solvent: clear colourless liquid.


  4. INDICATION(S)


    Active immunisation of dogs from 6 weeks of age:

    • to prevent mortality and clinical signs caused by canine distemper virus,

    • to prevent mortality and clinical signs caused by canine adenovirus type 1,

    • to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,

    • to prevent clinical signs, leucopoenia and viral excretion caused by canine parvovirus, and

    • to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus.


      Onset of immunity:

    • 3 weeks after the first vaccination for CDV, CAV, CPV, and

    • 3 weeks after completion of the primary course for CPiV.


      Duration of immunity:

      At least three years following the primary vaccination course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2 and canine parvovirus. The duration of immunity against CAV-2 was not established by challenge. It was shown that 3 years after the vaccination CAV-2 antibodies are still present. Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.

      At least one year following the primary vaccination course for canine parainfluenza virus.


  5. CONTRAINDICATIONS


    None.


  6. ADVERSE REACTIONS


    A transient swelling (up to 5 cm) may commonly be observed at the injection site following subcutaneous administration in dogs. This can be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination.


    Anorexia and decreased activity are rarely observed.


    Hypersensitivity reactions (e.g. gastrointestinal signs such as diarrhoea and vomiting, anaphylaxis, angioedema, dyspnoea, circulatory shock, collapse) may occur rarely. If such a reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition, which may be life-threatening.

    Systemic reactions such as lethargy, hyperthermia and general malaise may occur very rarely. The frequency of adverse reactions is defined using the following convention:

    • very common (more than 1 in 10 animals treated displaying adverse reaction(s))

    • common (more than 1 but less than 10 animals in 100 animals treated)

    • uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

    • rare (more than 1 but less than 10 animals in 10,000 animals treated)

    • very rare (less than 1 animal in 10,000 animals treated, including isolated reports).


    If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.


  7. TARGET SPECIES


    Dogs.

  8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION


    Subcutaneous use.


    Primary vaccination scheme:

    Two doses of Versican Plus DHPPi 3–4 weeks apart from 6 weeks of age.


    Leptospira:

    If protection against Leptospira is required dogs can be vaccinated with two doses of Versican Plus DHPPi mixed with Versican Plus L4 3–4 weeks apart from 6 weeks of age:

    The contents of a single vial of Versican Plus DHPPi should be reconstituted with the contents of a single vial of Versican Plus L4 (instead of the solvent). Once mixed, the contents of the vial should

    appear a whitish to yellowish colour with a slight opalescence. The mixed vaccines should be injected immediately via the subcutaneous route.


    Rabies:

    If protection against rabies is required:

    First dose: Versican Plus DHPPi from 8–9 weeks of age.

    Second dose: Versican Plus DHPPi mixed with Versiguard Rabies 3–4 weeks later, but not before 12 weeks of age.

    The contents of a single vial of Versican Plus DHPPi should be reconstituted with the contents of a single vial of Versiguard Rabies (instead of the solvent). Once mixed, the contents of the vial should appear a pink/red or yellowish colour with a slight opalescence. The mixed vaccines should be injected immediately via the subcutaneous route.

    The efficacy of the rabies fraction is proven after a single dose from 12 weeks of age in laboratory studies. However, in field studies 10% of seronegative dogs did not show seroconversion (>0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies. Some animals may also not show titres > 0.5 IU/ml after the primary vaccination. Antibody titres drop over the course of the 3-year duration of immunity, although dogs are protected when challenged. In case of travelling to risk areas or outside

    the EU, veterinary surgeons may wish to give additional rabies vaccinations after 12 weeks of age to ensure that the vaccinated dogs have an antibody titre of ≥ 0.5 IU/ml, which is generally regarded as sufficiently protective and that they meet the travel test requirements (antibody titres ≥ 0.5 IU/ml).


    Although the efficacy of the rabies fraction has been demonstrated following administration at 12 weeks, at the discretion of the veterinary surgeon, in case of need, dogs younger than 8 weeks can be vaccinated with Versican Plus DHPPi mixed with Versiguard Rabies as the safety of this association has been demonstrated in 6 week old dogs.


    Revaccination sche me:

    A single dose of Versican Plus DHPPi should be given every 3 years. Annual re-vaccination is

    required for Parainfluenza, therefore a single dose of compatible vaccine Versican Plus Pi can be used annually as required.


  9. ADVICE ON CORRECT ADMINISTRATION


    Aseptically reconstitute the lyophilisate with the solvent. Shake well and immediately inject the entire contents (1 ml) of the reconstituted product.


    Reconstituted vaccine: whitish to yellowish colour with a slight opalescence.

  10. WITHDRAWAL PERIOD(S)


    Not applicable.


  11. SPECIAL STORAGE PRECAUTIONS

    Keep out of the sight and reach of children. Store and transport refrigerated (2 °C – 8 °C).

    Do not freeze.

    Protect from light.

    Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP.

    Use immediately after reconstitution.


  12. SPECIAL WARNING(S)


    Special warnings for each target species:

    A good immune response is reliant on a fully competent immune system. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.


    Immunological responses to the CDV, CAV and CPV components of the vaccine may be delayed due to maternally derived antibody interference. However, the vaccine has been proven to be protective against virulent challenge in the presence of maternally derived antibodies to CDV, CAV and CPV at levels equal or higher to those likely to be encountered under field conditions. In situations where very high maternally derived antibody levels are expected, the vaccination protocol should be planned accordingly.


    Vaccinate healthy animals only.


    Spe cial precautions for use in animals:

    The live attenuated virus vaccine strains CAV-2, CPiV and CPV-2b may be shed by vaccinated dogs following vaccination, shedding of CPV has been shown for up to 10 days. However, due to the low pathogenicity of these strains, it is not necessary to keep vaccinated dogs separated from non-

    vaccinated dogs and domestic cats. The vaccine virus strain CPV-2b has not been tested in other carnivores (except dogs and domestic cats) that are known to be susceptible to canine parvoviruses and therefore vaccinated dogs should be separated from them after vaccination.


    Spe cial precautions to be take n by the pe rson administering the ve terina ry medicina l produc t to animals: In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.


    Pregna nc y and lactation:

    Can be used during the second and third stages of pregnancy. Safety of the product during the early stage of pregnancy and during lactation have not been investigated.


    Interaction with othe r medicina l produc ts and othe r forms of interaction:

    No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product other than Versiguard Rabies and Versican Plus L4. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

    Ove rdose (symptoms, emerge nc y proc edures, antidotes):

    No other adverse effects other than those mentioned under “Adverse reactions” have been observed after administration of a 10-fold overdose of the vaccine. However, in a minority of animals pain was observed at the injection site immediately after administration of a 10-fold overdose of the vaccine.


    Incompatibilit ie s:

    Do not mix with any other veterinary medicinal product other than those mentioned above.


  13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY


    Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.


  14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED


    https://www.ema.europa .eu/).


  15. OTHER INFORMATION


Plastic box containing 25 vials (1 dose) of lyophilisate and 25 vials (1 ml) of solvent. Plastic box containing 50 vials (1 dose) of lyophilisate and 50 vials (1 ml) of solvent.


Not all pack sizes may be marketed.